Indian pharma giant Wockhardt announced (in a press release Here) a settlement and license agreement with innovator Orion Corporation w.r.t it’s pending patent litigation on anti-Parkinson medication Comtan (Entacapone) and Stalevo (Carbidopa+Entacapone+Levodopa) tablets. Following patents are listed in orange book for Comtan (Entacapone) and Stalevo (Carbidopa+Entacapone+Levodopa) tablets:
US4963590 (Expiry: Nov 27, 2007): Claims Pharmaceutical composition and method of use of catechol-O-methyl transferase inhibitor
US5112861 (Expiry: May 12, 2009): Method of use with Entacapone and levodopa
US5135950 (Expiry: Oct 31, 2010): Crystallographically essentially pure polymorphic form A
US5446194 (Expiry: Oct 19, 2013): Covers Entacapone as product
US6500867(Expiry: Jun 29, 2020): Covers An oral solid tablet composition comprising pharmacologically effective amounts of Entacapone, Levodopa, and Carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and a pharmaceutically acceptable excipient, wherein a substantial portion of carbidopa or a pharmaceutically acceptable salt or hydrate thereof is separated from entacapone and levodopa or pharmaceutically acceptable salts or hydrates thereof in the tablet.
US6797732 (Expiry: Jun 29, 2020): A stable oral solid composition comprising pharmacologically effective amounts of active agents consisting of Entacapone, Levodopa, and Carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient other than microcrystalline cellulose
US6599530 (Expiry: Sep 14, 2018): Which covers an oral compacted composition in the form of a tablet, which comprises a pharmaceutically effective amount of entacapone, nitecapone, or pharmaceutically acceptable salt of entacapone or nitecapone, and croscarmellose sodium in an amount of at least 6% by weight of the composition.
Earlier, Wockhardt's challenged innovator’s ‘950, ‘194, ‘867, ‘530 and ‘732 patents listed in the Orange Book.
Subsequently, innovator Orion sued Wockhardt for patent infringement in the District Court of Delaware. Additionally, Orion filed the first lawsuit in the US in 2007 and thereafter two additional lawsuits were filed in 2008. The settlement agreement relates to all three suits.
Under the terms of the settlement agreement, Wockhardt will be able to launch generic versions of Comtan and Stalevo on September 30, 2012, or possibly even earlier, subject to certain conditions. Additional terms related to the settlement remain confidential, and the agreement is subject to review by the US Department of Justice and the U.S Federal Trade Commission (FTC).
Wockhardt is first Para IV filer on Entacapone tablets (Comtan) and accordingly, is eligible for 180 days First To File generic exclusivity as per Hatch-Waxman provisions.
Also, another generic player Sun Pharma has filed Para IV on this product and innovator has sued Sun Pharma in District Court of Delaware
USFDA Approvals
USFDA approved Comatan (Entacapone) 200 mg tablets on Oct 19, 1999 and
Stalevo (CARBIDOPA; ENTACAPONE; LEVODOPA) NDA for 12.5MG;200MG;50MG, 25MG;200MG;100MG and 37.5MG;200MG;150MG strength on Jun 11, 2003. Recently, USFDA approved new strengths of Stalevo (CARBIDOPA; ENTACAPONE; LEVODOPA) 50MG;200MG;200MG (approved on Aug 2, 2007), 18.75MG;200MG;75MG (approved on Aug 29, 2008), and 31.25MG;200MG;125MG (approved on Aug 29, 2008)
About Entacapone
Entacapone is a catechol-O-methyl transferase inhibitor for the treatment of Parkinson's disease. When administered in conjunction with dopaminergic agents such as L-DOPA, Entacapone increases the bioavailability of these compounds by facilitating their passage across the blood-brain barrier.